HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Research Dictionary Pharma Mobile

Sign Up FREE or Login

IQM-97,423

Subscribe to New Research on IQM-97,423

potent and selective CCK1 receptor antagonist with protective effect in experimental acute pancreatitis; structure in first source

Also Known As:

(4aS,5R)-2-benzyl-5-(tert-butylaminocarbonyl-tryptophyl)amino-1,3-dioxoperhydropyrido-(1,2-c)pyrimidine; IQM97423

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 319
    - Pyrimidinones: 14
      - IQM-97,423: 1

Experts

1.	Bartolomé-Nebreda, J M: 1 article (10/2004)
2.	García-López, M T: 1 article (10/2004)
3.	Herranz, R: 1 article (10/2004)
4.	Del Río, J: 1 article (10/2004)
5.	Cenarruzabeitia, E: 1 article (10/2004)
6.	Latorre, M: 1 article (10/2004)
7.	González-Muñiz, R: 1 article (10/2004)

Related Diseases

1.

10/01/2004 - "Pharmacological study of IQM-97,423, a potent and selective CCK1 receptor antagonist with protective effect in experimental acute pancreatitis."
10/01/2004 - "Consequently, the pyridopyrimidine derivative IQM-97,423 is a potent and highly selective CCK1 receptor antagonist with preventive effects in two experimental models of acute pancreatitis and a potential therapeutic interest."
10/01/2004 - "In common bile-pancreatic duct ligature-induced acute pancreatitis, IQM-97,423 partially prevented, like devazepide, the increase in plasma pancreatic enzyme activity and in pancreas weight. "
10/01/2004 - "The protective effect of IQM-97,423 and devazepide was tested in two models of acute pancreatitis in rats, induced by injection of cerulein or by combined bile and pancreatic duct obstruction. "

Related Drugs and Biologics

1.	Devazepide
2.	Caerulein (Ceruletide)

Related Therapies and Procedures

1.	Ligation